NASD · Healthcare · Diagnostics & Research · USA
Adaptive Biotechnologies Corp is a mid cap company (market value between $2 billion and $10 billion) in the Diagnostics & Research industry.
Adaptive Biotechnologies uses proprietary sequencing technology to decode patients' adaptive immune systems for disease diagnosis and treatment. Its MRD business offers clonoSEQ, an FDA-authorized test measuring minimal residual disease in lymphoid cancers, to clinicians and biopharmaceutical companies. The Immune Medicine business provides immune receptor sequencing and target discovery based on proprietary datasets of immune signatures and receptor-antigen matches.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Adaptive Biotechnologies Corp stock.
Overvalued: intrinsic value $4.67 per share, market price $28.49, margin of safety -509.9% (as of 2026-11-17).
A 2.7x revenue multiple, discounted for its losses, values the shares at $4.67; the price of $28.49 is 510% above that value.
17 more funds hold it; the full list is part of the paid plan.
All 44 Diagnostics & Research stocks
19 more in this industry show a wider margin of safety.
ADPT is overvalued (as of the 2026-11-17 close). A 2.7x revenue multiple, discounted for its losses, values the shares at $4.67; the price of $28.49 is 510% above that value.
$4.67 per share (as of the 2026-11-17 close), against a market price of $28.49. That is a margin of safety of -509.9%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.